We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-6.58%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.73B
AUM Growth
-$470M
Cap. Flow
-$39.5M
Cap. Flow %
-1.06%
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
23
Closed
9

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$46.8M
2
PEN icon
Penumbra
PEN
+$38.2M
3
BPMC
Blueprint Medicines
BPMC
+$26.6M
4
ABOS icon
Acumen Pharmaceuticals
ABOS
+$17.4M
5
AMGN icon
Amgen
AMGN
+$17M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$44.5M
2
PODD icon
Insulet
PODD
+$40.1M
3
CNMD icon
CONMED
CNMD
+$27.9M
4
ABCM
Abcam PLC
ABCM
+$26M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.04%
2 Consumer Staples 1.17%
3 Industrials 0.83%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
1
Humana
HUM
$43.7B
$212M 5.69%
436,500
-33,500
-7% -$15.7M
IMCR icon
2
Immunocore
IMCR
$1.72B
$153M 4.09%
2,943,710
-84,700
-3% -$5.01M
AGL icon
3
Agilon Health
AGL
$1.53B
$147M 3.95%
331,700
+400
+0.1% +$181K
NBIX icon
4
Neurocrine Biosciences
NBIX
$16.8B
$139M 3.72%
1,236,000
-43,500
-3% -$4.58M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$135M 3.61%
2,685,294
+498,622
+23% +$26.6M
ARGX icon
6
argenx
ARGX
$53.4B
$127M 3.41%
259,000
-91,000
-26% -$44.5M
PEN icon
7
Penumbra
PEN
$12.7B
$122M 3.26%
503,750
+137,750
+38% +$38.2M
UNH icon
8
UnitedHealth
UNH
$376B
$116M 3.11%
230,000
– –
EVH icon
9
Evolent Health
EVH
$348M
$105M 2.82%
3,865,000
+61,500
+2% +$1.71M
ISRG icon
10
Intuitive Surgical
ISRG
$127B
$87.2M 2.34%
298,500
– –
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$85.5M 2.29%
505,433
+11,906
+2% +$2.24M
IDXX icon
12
Idexx Laboratories
IDXX
$44.1B
$85M 2.28%
194,500
– –
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$84.9M 2.27%
400,200
– –
WST icon
14
West Pharmaceutical
WST
$24B
$75.8M 2.03%
202,000
– –
AKRO
15
DELISTED
Akero Therapeutics
AKRO
$71.8M 1.92%
1,419,150
-131,604
-8% -$6.13M
EXAS
16
DELISTED
Exact Sciences
EXAS
$69.5M 1.86%
1,018,250
+74,750
+8% +$6.34M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$1.79B
$67.1M 1.8%
2,710,061
+23,894
+0.9% +$632K
ALGN icon
18
Align Technology
ALGN
$12.1B
$66.3M 1.77%
217,000
– –
ACHC icon
19
Acadia Healthcare
ACHC
$2.76B
$63.8M 1.71%
908,000
– –
BSX icon
20
Boston Scientific
BSX
$69.5B
$61.2M 1.64%
1,160,000
+892,500
+334% +$46.8M
PODD icon
21
Insulet
PODD
$11.5B
$60.6M 1.62%
380,000
-179,000
-32% -$40.1M
MIRM icon
22
Mirum Pharmaceuticals
MIRM
$6.46B
$57.5M 1.54%
1,820,733
– –
CERE
23
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$55.2M 1.48%
2,529,116
+15,200
+0.6% +$380K
DXCM icon
24
DexCom
DXCM
$31.5B
$54.5M 1.46%
584,000
+93,500
+19% +$10.5M
RARE icon
25
Ultragenyx Pharmaceutical
RARE
$2.45B
$52.6M 1.41%
1,476,441
+92,172
+7% +$3.65M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rock Springs Capital Management held 129 positions worth $3.73B, down 11% from $4.2B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management's Q3 2023 filing shows 6 new, 41 increased, 23 reduced and 9 closed positions. Its largest new stake was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M. The largest sale was argenx, an estimated $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2023 buy was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2023, an estimated $46.8M increase.
  • Rock Springs Capital Management's biggest Q3 2023 reduction was argenx, cutting an estimated $44.5M.
  • Rock Springs Capital Management fully exited CONMED in Q3 2023, selling an estimated $27.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.73B portfolio in Q3 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 9 in Q3 2023.
  • Rock Springs Capital Management's portfolio value fell 11% quarter-over-quarter to $3.73B.

Based on Rock Springs Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.